Impact of HD or TD
on Quality of Life

Teva recently undertook a research survey to ask the general public in the US about the impact of tardive dyskinesia (TD) or the chorea associated with Huntington’s disease (HD) on quality of life.

The responses from the survey were used to calculate utility values, which are used to help assess the burden of disease. To date, no studies have reported utility values specifically for HD chorea and there are limited data on the quality of life and social consequences of TD.

This research collaboration was interested in understanding how people would choose between a shorter life spent in full health or living longer but with HD or TD.

The aim was to highlight what it would be like to live with the symptoms.

Huntington’s
Disease survey

Evaluation of health states to understand people’s opinions on Huntington’s disease.

Take the HD survey

Tardive
Dyskinesia survey

Watch this short video and complete the survey that follows to learn more about our research project

Take the TD survey

Utility values

Close

Utilities are values that reflect an individual’s preferences for different health outcomes and reflect societal perceived disease severity. They are typically measured on a scale, with zero reflecting states of health equivalent to death and one reflecting perfect health. They are used by decision-makers to more accurately assess treatment benefit.

References: What_are_health_util.pdf (bandolier.org.uk) 2021 American Academy of Neurology Abstract Website (mirasmart.com) (Claassen et al AAN 2021)

References

Close

HD References

AAN 2021 HD Utility Encore Poster

Additional References
1. Bates GP, et al. Nat Rev Dis Primers. 2015;1:15005.
2. Ross CA, et al. Nat Rev Neurol. 2014;10(4):204-216.
3. Thorley EM, et al. Patient. 2018;11(5):547-559.
4. Ho AK, et al. Clin Genet. 2011;80(3):235-239.
5. Hawton A, et al. Eur J Health Econ. 2019;20(9):1335-1347.
6. van Walsem MR, et al. Health Qual Life Outcomes. 2017;15(1):6.
7. Dorey J, et al. J Mark Access Health Policy. 2016;4.
8. Bleichrodt H, Johannesson M. J Health Econ. 1997;16(2):155-175.
9. Bleichrodt H. Health Econ. 2002;11(5):447-456.
10. van Osch SM, et al. Med Decis Making. 2004;24(5):511-517.
11. Wright DR, et al. Pharmacoeconomics. 2009;27(9):713-723.
12. What_are_health_util.pdf (bandolier.org.uk)
13. 2021 American Academy of Neurology Abstract Website (mirasmart.com) (Claassen et al AAN 2021)

TD References

WPA 2021 TD Utility poster

Additional References
1. Waln O, Jankovic J. Tremor Other Hyperkinet Mov (N Y). 2013;3:1-11.
2. Boumans CE, et al. Schizophr Bull. 1994;20(2):339-344.
3. Ayyagari R, et al. CNS Spectr. 2020;25(2):275-276.
4. Bleichrodt H. Health Econ. 2002;11(5):447-456.
5. van Osch SMC, et al. Med Decis Making. 2004;24(5):511-517.
6. Wright DR, et al. Pharmacoeconomics. 2009;27(9):713-723.
7. Bleichrodt H, Johannesson M. J Health Econ. 1997;16(2):155-175.
8. What_are_health_util.pdf (bandolier.org.uk)
9. 2021 American Academy of Neurology Abstract Website (mirasmart.com)